





















47. Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral Tregs via activating FcγR2b, leading to antitumor efficacy. *Immunol Cell Biol* 2014;2:475–80.
48. Haas LF. Neurological stamp: Paul Ehrlich (1854–1915) and Emil Adolf von Behring (1854–1917). *J Neurol Neurosurg Psychiatry* 2001;70:678.
49. Brady LJ. Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens. *Infect Immun* 2005;73:671–8.
50. Berlyn KA, Schultes B, Leveugle B, Noujaim AA, Alexander RB, Mann DL. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. *Clin Immunol* 2001;101:276–83.
51. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. *J Clin Invest* 2002;110:71–9.
52. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating FcγR2b on dendritic cells. *J Exp Med* 2002;195:1653–9.
53. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, et al. FcγR2b-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. *J Exp Med* 1999;189:371–80.
54. de Bono JS, Rha SY, Stephenson J, Schultes BC, Monroe P, Eckhardt GS, et al. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. *Ann Oncol* 2004;15:1825–33.
55. Taylor C, Hershman D, Shah N, Suci-Foca N, Petrylak DP, Taub R, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. *Clin Cancer Res* 2007;13:5133–43.
56. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. *Blood* 2004;104:2635–42.
57. Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. *Blood* 2009;113:3809–12.
58. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. *N Engl J Med* 1992;327:1209–15.
59. Selenko N, Majdic O, Jager U, Sillaber C, Stockl J, Knapp W. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? *J Clin Immunol* 2002;22:124–30.
60. Gadri Z, Kukulansky T, Bar-Or E, Haimovich J, Hollander N. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma. *J Immunother* 2009;32:333–40.
61. Abes R, Gelize E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. *Blood* 2010;116:926–34.
62. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med* 2013;369:122–33.
63. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. *Ann Oncol* 2013;24:75–83.
64. Slovin SF, Higo CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. *Ann Oncol* 2013;24:1813–21.